Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open
News
NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people with Alzheimer’s disease, following authorization by the U.S. Food and Drug ... Read more